Navigation Links
Genetic predisposition increases childhood asthma risk
Date:8/20/2007

Children who carry variations in specific genes that metabolize vehicle emissions are more susceptible to developing asthma, particularly if they live near major roadways, a study led by researchers at the University of Southern California (USC) suggests.

Researchers found that children who carried variations in two genes and lived within 75 meters of a major road were up to nine times more likely to develop asthma than children who lived further away, says Muhammad T. Salam, Ph.D. candidate at the Keck School of Medicine of USC, and the studys lead author. The study will appear in the journal Thorax, and is now available online.

This is one of the first studies to report that children with certain genetic backgrounds are even more susceptible to asthma than if they lived near major roads and did not carry the variations, Salam says. We are working to understand how traffic-related exposures may interact with these genes, leading to asthma development.

Asthma is the most common chronic disease in children, and previous studies have shown that traffic-related pollution near the home increases asthma risk and reduces lung growth, according to USC experts.

Researchers drew upon data from the Childrens Health Study (CHS), a longitudinal study of respiratory health among school-age children in 12 Southern California communities. They compared associations between number of genetic variants and exposure to toxins among more than 3,000 study participants.

Researchers found that high levels of microsomal epoxide hydrolase (EPHX1)an enzyme that metabolizes polyaromatic hydrocarbons (PAH) in vehicle emissionswas associated with an increased risk for lifetime asthma. Children with high EPHX1 levels who also carried variations in glutathione S-transferase P1 (GSTP1) genes were four times more likely to have asthma.

Among children who lived within 75 meters of a major road, those with high EPHX1 activity were three times
'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
2. Crowning glory of 2000!!! Cracking of the genetic code is top of tops
3. Genetic influence in menopause
4. Genetics and cholesterol levels
5. Genetics helps in attacking cancer
6. DNA biochip for genetic screening
7. Genetic disorder related with sleep patterns
8. Genetic innovation
9. Sleepwalking has genetic roots
10. A new genetic label for stroke
11. Genetic tests for cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...h Annual Physician On-Call Pay .../ -- Sullivan, Cotter and Associates, Inc.,has pub...ll pay rates and,practices, the 2008 Physician On-...ta from 132 healthcare organizations nationwide, o...paid for 33 physician specialty areas along,with d...
(Date:7/25/2008)...lusivity Begins -, CORONA, Calif., July 25 /PRNew...NYSE: WPI ), a leading specialty pharmaceutical,c...mmenced commercial,shipment of its Omeprazole Dela...gth from its Davie, Florida manufacturing facility...ays of marketing exclusivity for being the,first t...
(Date:7/25/2008)...ert J. Reilly, Joins Aethon Team, PITTSBURGH, Jul...on.com ), the leading developer of mobile robotics...ced that Robert J. Reilly has,joined the company a...., Reilly, who was most recently Vice President -...alty Pharmacy Division, brings more than 30,years ...
(Date:7/25/2008)...ekta Family of Companies will,showcase their uniqu...merican Association of Physicists in Medicine (AAP...ces of Elekta, IMPAC and CMS are delivering,cuttin...utions that,streamline the treatment process to cr...enhance clinician efficiency., "Our recent acquis...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...ther the reasons for swallowing the mobile phone b...or she purposely swallowed the mobile phone. // Th... in which it is said that the young lady purposely...th her boy friend in which she did not want to giv...
... two Israeli ophthalmologists Professor Michael Be...schleger Eye Institute at the Sheba Medical Centre...; They said that they have co-related all the prev...me out with strong evidences that obesity is the c...
...ave reported to have dead chicken and the cause th...ad chickens were tested and they showed positive r...placed an eastern town under scrutiny and have bee... of disease to other birds. The virus was first d...
...e polio eradication programme, initiated before 17...ent regions of the world. The programme was aimed ...of 2005. // The initiative, started in 1988, had a...adline has been set, and success may depend, in pa...
Other Medicine News:Health News:Increased Risk Of Losing Sight In Obese People. 2Health News:The Slow And Steady Race To Eradicate Polio Offers Hope 2
(Date:7/23/2008)...ing publication in July print edition of Clinical ... INDIANAPOLIS, July 23 /- A Roche Dia...of N-terminal pro-B-type natriuretic peptide,(NT-p...or risk,stratification in predicting the risk of c...reated with non-steroidal anti-inflammatory drugs ...
(Date:7/23/2008)...y 23 /- InCode BioPharmaceutics, Inc....ounced preclinical test,results demonstrating the ... treatment of the rare chronic blood disorder paro...e results will be presented at the XXII,Internatio...tember 28,2008., The only treatment currently av...
(Date:7/22/2008)...22 /- Nonin Medical, a leading innova... than 20 years, has entered,the clinical testing p...egional oxygen saturation. Today,s most common app...itoring of the regional blood oxygenation,in the b...d outcomes from an ongoing clinical study at the,D...
(Date:7/22/2008)...ing Lantus(R) and Apidra(R) Resulted in Significan...tes, Whatever the Algorithm ...wswire/ -- Results from the "Adjust to,Target in T...o Carbohydrate,Counting for Adjustment of Mealtime...merican Diabetes Association,s (ADA) medical journ...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 1TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 2TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 3TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 4TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 5TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 6TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 7Psychology com Seeing Growing Acceptance of Online Therapy 19145 1Psychology com Seeing Growing Acceptance of Online Therapy 19145 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 1Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 3Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 4Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 5Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 6Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 7NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 1NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 3
...VERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inot... presentation of,positive Phase 2 clinical data de...potential for INO-1001 as a preventative agent for...ed in subjects,with acute ST-elevated myocardial i...coronary intervention. The presentation was,made i...
...ETHESDA, Md., March 27, 2007--A new study shows th...e proportion of,cardiovascular disease (CVD) linke... emphasize the need for increased efforts to,preve...CVD risk,factors among those with diabetes, accord...amingham Heart Study, a program of the,National He...
Other Medicine Technology:Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings
Non-Cantilevered, "Teardrop" Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter.
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company.
...dule is an inconspicuous, lightweight, battery-ope...need to hear body functions amplified., ,The modu... integrated on/off switch, a tone switch, a stetho... The tone switch will allow the user to select bet...
Medicine Products: